Efficacy and safety of ODM-104 compared to a standard combination (Stalevo); a randomised, double-blind, crossover proof-of-concept study in patients with Parkinson's disease and end-of-dose wearing-off

Trial Profile

Efficacy and safety of ODM-104 compared to a standard combination (Stalevo); a randomised, double-blind, crossover proof-of-concept study in patients with Parkinson's disease and end-of-dose wearing-off

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2017

At a glance

  • Drugs ODM 104 (Primary) ; Carbidopa; Levodopa; Levodopa/carbidopa/entacapone
  • Indications Parkinson's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms COMPOC
  • Sponsors Orion
  • Most Recent Events

    • 13 Oct 2017 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018.
    • 13 Oct 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Mar 2018.
    • 30 Jun 2017 Last checked against European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top